The Vehicle, Fall 2006

Table of Contents Ferris WheelEmily Daviscover HerStephen Jefferiespage 1 UntitledBob Freyderpage 2 Writing at O\u27BrienWillie Joseph Morrispage 3 Blanks and HabitsRebecca M. Griffithpage 4 Soldier\u27s NightmareCraig A. Dennispage 5 UntitledLindsey Durbinpage 6 A Slow, Painless DeathJacob Fosterpage 7 ThoughtAmanda Yealepage 8 The SociopathBob Freyderpage 9 EasyRebecca M. Griffithpage 10 My PartnerDiedre Mapespage 11 BarriersSuzanne Krahnpage 12 The mind is a prisonJordan Hohespage 13 We Were Shirtless When Thousands DiedMitch Jamespage 14 ComplaintAmanda Yealepage 15 UntitledBob Freyderpage 16 MarkedAmanda Yealepage 17 She Wears Red Lipstick, He, Heartsick EyesRebecca M. Griffithpage 18 PrayerAmanda Yealepage 19 HomeDeej Rolewskipage 20 Your DreamDiedre Mapespage 21 Even Fingers Get LonelySuzanne Krahnpage 22 AggressivityMitch Jamespage 23 FallenMitch Jamespage 24 CollapseMario Podeschipage 36 The Italian CrisisAndy Masterspage 41 About the Authorshttps://thekeep.eiu.edu/vehicle/1084/thumbnail.jp

The Vehicle, Fall 2006

Table of Contents Ferris WheelEmily Daviscover HerStephen Jefferiespage 1 UntitledBob Freyderpage 2 Writing at O\u27BrienWillie Joseph Morrispage 3 Blanks and HabitsRebecca M. Griffithpage 4 Soldier\u27s NightmareCraig A. Dennispage 5 UntitledLindsey Durbinpage 6 A Slow, Painless DeathJacob Fosterpage 7 ThoughtAmanda Yealepage 8 The SociopathBob Freyderpage 9 EasyRebecca M. Griffithpage 10 My PartnerDiedre Mapespage 11 BarriersSuzanne Krahnpage 12 The mind is a prisonJordan Hohespage 13 We Were Shirtless When Thousands DiedMitch Jamespage 14 ComplaintAmanda Yealepage 15 UntitledBob Freyderpage 16 MarkedAmanda Yealepage 17 She Wears Red Lipstick, He, Heartsick EyesRebecca M. Griffithpage 18 PrayerAmanda Yealepage 19 HomeDeej Rolewskipage 20 Your DreamDiedre Mapespage 21 Even Fingers Get LonelySuzanne Krahnpage 22 AggressivityMitch Jamespage 23 FallenMitch Jamespage 24 CollapseMario Podeschipage 36 The Italian CrisisAndy Masterspage 41 About the Authorshttps://thekeep.eiu.edu/vehicle/1084/thumbnail.jp

Gerontological Society of America

Objectives: The aim of this study was to examine the association between conscious monitoring and control of movements (i.e., movement specific reinvestment) and visuo-motor control during walking by older adults. Method: The Movement Specific Reinvestment Scale (MSRS; Masters, Eves, & Maxwell, 2005) was administered to ninety-two community-dwelling older adults, aged 65-81 years, who were required to walk along a 4.8-meter walkway and step on the middle of a target as accurately as possible. Participants’ movement kinematics and gaze behavior were measured during approach to the target and when stepping on it. Results: High scores on the MSRS were associated with prolonged stance and double support times during approach to the stepping target, and less accurate foot placement when stepping on the target. No associations between MSRS and gaze behavior were observed. Discussion: Older adults with a high propensity for movement specific reinvestment seem to need more time to “plan” future stepping movements, yet show worse stepping accuracy than older adults with a low propensity for movement specific reinvestment. Future research should examine whether older adults with a higher propensity for reinvestment are more likely to display movement errors that lead to fallin

17th IEEE Real-Time Systems Symposium: Work in Progress Sessions

The Table of Contents for the workshop is contained in 1996-027-00main.pdfDear Colleagues: This year marks the beginning of a new tradition within the Real-Time Systems Symposium, that of holding special sessions for the presentation of new and on-going projects in real-time systems. The prime purpose of these Work In Progress (WIP) sessions is to provide researchers in Academia and Industry an opportunity to discuss their evolving ideas and gather feedback thereon from the real-time community at large. The idea of holding these sessions is timely, and I am pleased to report that this year RTSS'96 WIP received 22 submissions, of which 14 have been accepted for presentation during the symposium and for inclusion in RTSS'96 WIP proceedings. Many people worked hard to make the idea of holding the WIP sessions a reality. In particular, I would like to thank Sang Son for his hard work in accommodating the WIP sessions within the busy schedule of RTSS'96. Also, I would like to thank all members of the RTSS'96 Program Committee, Al Mok and Doug Locke in particular, for their encouragement and constructive feedback regarding the organization of these sessions. Finally, I would like to thank all those who submitted their work to RTSS'96 WIP and those from RTSS'96 program committee who helped review these submissions. I hope these sessions will prove beneficial, both to the WIP presenters and to RTSS'96 attendees. Azer Bestavros RTSS'96 WIP Chair December 1996.IEEE-CS TC-RT

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials